A new three -minute “brainwave” can detect the test Alzheimer’s Before diagnosis, according to a new study.
Researchers at Bath University said Current clinical equipment “Alzheimer’s first 10 to 20 years are missing”, but believe that a new “fastball” test can change in that way Disease is detected,
The 180-second “passive” test, which records electrical activity in the brain, while see a stream of participants, has been found to strengthen memory problems in people with mild cognitive loss (MCI)-a condition that can lead to Alzheimer’s.
For the first time, researchers have shown that the test may be in patients’ homes as well as GP surgery and memory clinics, which researchers say that low cost may be the key to addressing “immediate” requirement for more accessible screening.
He said that the success of the new Alzheimer’s “Miracle” drugs Donanmab and Lenkainmab means that early diagnosis is “more important than ever”.
Donanemab and lecanemab Targeted antibodies are drugs that slow down the early stages of Alzheimer’s, which are bound by amyloid, which is a protein that makes the brain of people living with Alzheimer’s disease. Drugs, which are Currently not available on NHSThey prove most effective in the early stages of Alzheimer’s.
Researchers described fastball as an inactive EEG (electroceleogram) test, which uses the sensor placed on the skull to monitor the brain for images without asking participants to follow the instructions or to recall information. He said that this makes the test more accessible and purposeful than traditional memory tests.
Along with fastball testing, patients with tests also completed many neurocycical assessments, continuous attention and general cognitive function of memory.
Researchers found that the main symptoms with Amnastic MCI are significant memory loss, such as forgetting appointments and recent interactions-shown much less reactions to fastball testing compared to people with patients and non-enemy MCIs.
Researchers re-tested the group after a year and showed fastball “medium to moderately better test-rit-reliability” in healthy old adults.
The study was led by Dr. George Stothart had a cognitive neurocystist in the Department of Psychology at Bath University. He said: “Exact, practical equipment is immediately needed to diagnose Alzheimer’s scale. Fastball is cheaper, portable, and works in real -world settings.”
It was funded by the Medical Sciences Academy and was supported by the dementia Research Charity Brace. CEO Chris Williams called Fastball an “incredible tool” and said that she is curious to see what the team can develop in the future.
“Fastball is an incredible device that can introduce anyone, which, for any reason, cannot reach a dementia diagnosis in the clinical setting,” he said. “Brace has been supporting the development of fastball for many years, and we are excited to see what the team of Dr. Stothart will achieve with the ongoing support from charity over the next few years.”
The Alzheimer’s Society estimates that the UK has around 982,000 people with dementia, but not diagnosed with more than a third. The number is expected to increase to 1.4 million by 2040.